CRISPR/Cas9-mediated PD-1 attenuation enhances tumor infiltrating lymphocyte-based adoptive cellular therapy in humanized-PDX model of hepatocellular carcinoma
Taken together, our results have provided a foundation for the clinical application of ACT based on genetically modified TIL, offering a new perspective on exploring clinical immunotherapy strategies for HCC, and potentially other solid tumors.
Authors
- Jianmin Wu (ORCID: https://orcid.org/0000-0002-5031-7431)
- Kedar Ghimire (ORCID: https://orcid.org/0000-0002-4672-5256)
- Wei Wang (ORCID: https://orcid.org/0000-0002-3409-7846)
- Muqi Liu (ORCID: https://orcid.org/0009-0007-7631-2798)
- Di Wu (ORCID: https://orcid.org/0000-0003-1249-9286)
- Yang Hu (ORCID: https://orcid.org/0000-0003-3468-452X)
- Pengfei Rong (ORCID: https://orcid.org/0000-0001-5473-1982)
- Juan Zhang (ORCID: https://orcid.org/0000-0003-3683-0092)
- Hao Liu (ORCID: https://orcid.org/0000-0003-1227-2954)
- Xiaoqian Ma
- Qi Liang (ORCID: https://orcid.org/0000-0002-0054-1478)
- Huaping Liu (ORCID: https://orcid.org/0000-0002-1434-7553)
- Yao Deng
- Wu Ge
Institutions
- Central South University (CN)
- Aarhus University (DK)
- Xiangya Hospital Central South University (CN)
- University of South China (CN)
Publication Details
- Journal
- Translational Oncology
- Published
- 2025-08-05
- DOI
- https://doi.org/10.1016/j.tranon.2025.102484
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Key Project of Research and Development Plan of Hunan Province
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province
- Science and Technology Program of Hunan Province